Accessibility and accommodation Novartis is committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you ...

Zaposlitev v Novartisu v Sloveniji V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni ...

Novartis ricerca costantemente nuovi talenti da inserire nel proprio organico. Visualizza le opportunità di impiego nelle diverse Divisioni e in tutti i paesi.

Careers at Novartis in Slovenia At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

Offene Stellen Rund 3.300 Mitarbeitende setzen sich bei Novartis Österreich gemeinsam dafür ein, das Leben von Patientinnen und Patienten zu verlängern und zu verbessern. Willst du dabei sein? Dann ...

Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...

V Novartisu přetváříme medicínu Jsme globální farmaceutickou společností, která působí ve 140 zemích světa a zaměstnává přibližně 110 tisíc lidí. Naším posláním je objevovat nová řešení, které ...

Product portfolio At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these ...

Modern Slavery Statement 2024 - Australia, Canada, and United Kingdom (PDF 0.3 MB) Our statement under UK, Canadian and Australian legislation on our efforts to address modern slavery. Norwegian ...

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of ...

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...